Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- New Drugs Make Up For Lipitor Patent Expiration: President Umeda of Pfizer
December 20, 2010
- Daiichi Sankyo Prioritizes 1st-in-Class Drugs in R&D: President Nakayama
December 20, 2010
- AZ's Ticagrelor Obtains EC Approval to Prevent Atherothrombotic Events in ACS
December 20, 2010
- Rifaximin to Drive ASKA's Business: President Yamaguchi
December 20, 2010
- BMS Applies for Additional Indication for SPRYCEL in Japan
December 20, 2010
- Sprycel Obtains EC Approval for a New Indication
December 20, 2010
- Novartis Recommends Rasilez for Use in First-Line Therapy
December 20, 2010
- Gov't Aims to Create Japanese Version of NIH
December 20, 2010
- FDA Advisory Committee Recommends Approval of Contrave for Obesity: Takeda
December 20, 2010
- MCHC Aims at Operating Profits of \120 Bil. for Healthcare Business in FY2015
December 20, 2010
- NCGM to Start IIT to Compare 3 Antidiabetic Drugs
December 20, 2010
- Pfizer to Develop Orphan Drugs Even if Profits Are Small: Mr Matsumori
December 20, 2010
- Teijin Pharma, Genzyme Aim at Peak Sales of ¥15 Bil. for Synvisc
December 20, 2010
- Edoxaban Significantly Prevents VTE after THR vs Enoxaparin: Daiichi Sankyo
December 20, 2010
- Generics Dispensing Rate Up to 22.8%: Korosho Survey
December 20, 2010
- Senju to Double Its Share in Glaucoma Market
December 20, 2010
- DSP Announces Results of 3rd PIII Trial of Latuda
December 20, 2010
- 60% of Pharmacies Claim Premiums for Generics Dispensing System: NPhA Survey
December 20, 2010
- Astellas Obtains Oncology Technology Platform from AVEO
December 13, 2010
- Itochu, PRISM BioLab to Market Library of Chemical Compounds
December 13, 2010
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…